Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailCabergoline in the treatment of hyperprolactinemia: a study in 455 patients.
Verhelst, Johan; Abs, Roger; Maiter, Dominique et al

in Journal of Clinical Endocrinology and Metabolism (1999), 84(7), 2518-22

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number ... [more ▼]

Cabergoline is a new long-acting dopamine agonist that is very effective and well tolerated in patients with pathological hyperprolactinemia. The aim of this study was to examine, in a very large number of hyperprolactinemic patients, the ability to normalize PRL levels with cabergoline, to determine the effective dose and tolerance, and to assess the effect on clinical symptoms, tumor shrinkage, and visual field abnormalities. We also evaluated the effects of cabergoline in a large subgroup of patients with bromocriptine intolerance or -resistance. We retrospectively reviewed the files of 455 patients (102 males and 353 females) with pathological hyperprolactinemia treated with cabergoline in 9 Belgian centers. Among these patients, 41% had a microadenoma; 42%, a macroadenoma; 16%, idiopathic hyperprolactinemia; and 1%, an empty sella. The median pretreatment serum PRL level was 124 microg/L (range, 16-26,250 microg/L). A subgroup of 292 patients had previously been treated with bromocriptine, of which 140 showed bromocriptine intolerance and 58 showed bromocriptine resistance. Treatment with cabergoline normalized serum PRL levels in 86% of all patients: in 92% of 244 patients with idiopathic hyperprolactinemia or a microprolactinoma and in 77% of 181 macroadenomas. Pretreatment visual field abnormalities normalized in 70% of patients, and tumor shrinkage was seen in 67% of cases. Side effects were noted in 13% of patients, but only 3.9% discontinued therapy because of side effects. The median dose of cabergoline at the start of therapy was 1.0 mg/week but could be reduced to 0.5 mg/week once control was achieved. Patients with a macroprolactinoma needed a higher median cabergoline dose, compared with those with idiopathic hyperprolactinemia or a microprolactinoma: 1.0 mg/week vs. 0.5 mg/week, although a large overlap existed between these groups. Twenty-seven women treated with cabergoline became pregnant, and 25 delivered a healthy child. One patient had an intended abortion and another a miscarriage. In the patients with bromocriptine intolerance, normalization of PRL was reached in 84% of cases, whereas in the bromocriptine-resistant patients, PRL could be normalized in 70%. We confirmed, in a large-scale retrospective study, the high efficacy and tolerability of cabergoline in the treatment of pathological hyperprolactinemia, leaving few patients with unacceptable side effects or inadequate clinical response. Patients with idiopathic hyperprolactinemia or a microprolactinoma, on average, needed only half the dose of cabergoline as those with macroprolactinomas and have a higher chance of obtaining PRL normalization. Cabergoline also normalized PRL in the majority of patients with known bromocriptine intolerance or -resistance. Once PRL secretion was adequately controlled, the dose of cabergoline could often be significantly decreased, which further reduced costs of therapy. [less ▲]

Detailed reference viewed: 85 (2 ULg)
See detailCabergoline, a new long-acting dopamine agonist, in the treatment of acromegaly
Abs, R.; Verhelst, J.; Verbessem, G. et al

in 10th international Congress of Endocrinology - Abstract book (1996)

Detailed reference viewed: 8 (0 ULg)
Full Text
See detailUna Cabeza Bien Hecha O Una Cabeza Repleta ?
Crahay, Marcel ULg

in Perspectivas (1996), XXVI(1),

Detailed reference viewed: 28 (2 ULg)
See detailCabinet de curiosités
Nazé, Yaël ULg

Article for general public (2012)

Detailed reference viewed: 31 (3 ULg)
Peer Reviewed
See detailCabinet de curiosités contemporains : de l'oeuvre au musée
Bawin, Julie ULg

Conference (2017, March 15)

Detailed reference viewed: 11 (0 ULg)
Full Text
See detailLe cabinet de papier de Jean Jacques Boissard (1528-1602). Réception de l’Antiquité et collectionnisme
De Marco, Rosa ULg

in Bourdieu, Catherine (Ed.) Collections et collectionneurs dans les Trois-Évêchés (2016, January)

Detailed reference viewed: 41 (2 ULg)
Peer Reviewed
See detailLe cabotin sublime et les pisse-froid. Sartre, Hugo et la modernité
Denis, Benoît ULg

in Prévost, Maxime; Hamel, Yan (Eds.) Victor Hugo 2003-1802. Images et transfigurations (2003)

Detailed reference viewed: 18 (0 ULg)
See detailcAbVIM4, a nanobody inhibiting the metallo-β-lactamase VIM-4
Sohier, Jean ULg; Laurent, Clémentine ULg; Pardon, Els et al

Poster (2010)

Detailed reference viewed: 18 (11 ULg)
See detailCAC40 et alternance politique : François Hollande et le monde des affaires
Geuens, Geoffrey ULg

Article for general public (2012)

Detailed reference viewed: 38 (15 ULg)
Full Text
See detailCacahuète céleste
Nazé, Yaël ULg

Article for general public (2014)

Detailed reference viewed: 22 (4 ULg)
See detailCachez cette loi que je ne saurais voir !
Orban, Lionel ULg

in Actualités du Droit (2001)

Detailed reference viewed: 19 (0 ULg)
See detailCaCO3 particles for drug delivery systems
Ergül, Zeynep ULg; Jérôme, Christine ULg; Debuigne, Antoine ULg et al

Scientific conference (2015, October 22)

Detailed reference viewed: 24 (3 ULg)
Full Text
Peer Reviewed
See detailCacophonie jurisprudentielle autour de la notion d’impôt
Rosoux, Géraldine ULg

in Revue de Jurisprudence de Liège, Mons et Bruxelles (2003)

The article analyzes a decision of the Belgian judicial Supreme Court concerning the concept of "tax", and emphasizes the conflict between this decision and the case-law of the Belgian constitutional Court

Detailed reference viewed: 98 (15 ULg)
Peer Reviewed
See detailCAD versus micro-CT based models of Ti6Al4V scaffolds for bone tissue engineering: a solid and fluid mechanical analysis
Truscello, Silvia; Kerckhofs, Greet ULg; Moesen, Maarten et al

in Proceedings of II International Conference on Tissue Engineering (2011)

Detailed reference viewed: 13 (1 ULg)
Full Text
See detailCAD/FEM Coupling in Shape Optimization
Morelle, P.; Duysinx, Pierre ULg; Fleury, Claude ULg

Conference (1992, November)

Detailed reference viewed: 40 (4 ULg)
See detailCadastre des infrastructures: problèmes et recommandations. Provinces du Nord et Sud-Kivu
Kabamba, Bob ULg

Book (2010)

L'ouvrage vise à contribuer à la stratégie de stabilisation et de reconstruction des provinces du Nord et Sud Kivu.

Detailed reference viewed: 67 (5 ULg)
Full Text
Peer Reviewed
See detailCadaveric liver transplantation for non-acetaminophen fulminant hepatic failure: A 20-year experience
Detry, Olivier ULg; De Roover, Arnaud ULg; Coimbra Marques, Carla ULg et al

in World Journal of Gastroenterology (2007), 13(9), 1427-1430

AIM: To investigate the long-term results of liver transplantation (LT) for non-acetaminophen fulminant hepatic failure (FHF). METHODS: Over a 20-year period, 29 FHF patients underwent cadaveric whole LT ... [more ▼]

AIM: To investigate the long-term results of liver transplantation (LT) for non-acetaminophen fulminant hepatic failure (FHF). METHODS: Over a 20-year period, 29 FHF patients underwent cadaveric whole LT. Most frequent causes of FHF were hepatitis B virus and drug-related (not acetaminophen) liver failure. All surviving patients were regularly controlled at the out-patient clinic and none was lost to follow-up. Mean follow-up was 101 mo. RESULTS: One month, one-, five- and ten-year patient survival was 79%, 72%, 68% and 68%, respectively. One month, one-, five- and ten-year graft survival was 69%, 65%, 51% and 38%, respectively. Six patients needed early (< 2 mo) retransplantation, four for primary non-function, one for early acute refractory rejection because of ABO blood group incompatibility, and one for a malignant tumor found in the donor. Two patients with hepatitis B FHF developed cerebral lesions peri-transplantion: One developed irreversible and extensive brain damage leading to death, and one suffered from deep deficits leading to continuous medical care in a specialized institution. CONCLUSION: Long-term outcome of patients transplanted for non-acetaminophen FHF may be excellent. As the quality of life of these patients is also particularly good, LT for FHF is clearly justified, despite lower graft survival compared with LT for other liver diseases. (C) 2007 The WJG Press. All rights reserved. [less ▲]

Detailed reference viewed: 83 (21 ULg)
Full Text
Peer Reviewed
See detailCadaveric VOC Profiles for Forensic Investigations
Stefanuto, Pierre-Hugues ULg; Stadler, S; Forbes, S et al

Conference (2013, June)

Detailed reference viewed: 18 (5 ULg)